Glioma pp 109-120 | Cite as

Adoptive Cell Transfer Therapy For Malignant Gliomas

  • Eiichi Ishikawa
  • Shingo Takano
  • Tadao Ohno
  • Koji Tsuboi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 746)

Abstract

To date, various adoptive immunotherapies have been attempted for treatment of malignant gliomas using nonspecific and/or specific effector cells. Since the late 1980s, with the development of rIL-2, the efficacy of lymphokine-activated killer (LAK) cell therapy with or without rIL-2 for malignant gliomas had been tested with some modifications in therapeutic protocols. With advancements in technology, ex vivo expanded tumor specific cytotoxic T-lymphocytes (CTL) or those lineages were used in clinical trials with higher tumor response rates. In addition, combinations of those adoptive cell transfer using LAK cells, CTLs or natural killer (NK) cells with autologous tumor vaccine (ATV) therapy were attempted. Also, a strategy of high-dose (or lymphodepleting) chemotherapy followed by adoptive cell transfer has been drawing attentions recently. The most important role of these clinical studies using cell therapy was to prove that these ex vivo expanded effector cells could kill tumor cells in vivo. Although recent clinical results could demonstrate radiologic tumor shrinkage in a number of cases, cell transfer therapy alone has been utilized less frequently, because of the high cost of ex vivo cell expansion, the short duration of antitumor activity in vivo, and the recent shift of interest to vaccine immunotherapy. Nevertheless, NK cell therapy using specific feeder cells or allergenic NK cell lines have potentials to be a good choice of treatment because of easy ex vivo expansion and their efficacy especially when combined with vaccine therapy as they are complementary to each other. Also, further studies are expected to clarify the efficacy of the high-dose chemotherapy followed by a large scale cell transfer therapy as a new therapeutic strategy for malignant gliomas.

Keywords

Toxicity Catheter Shrinkage Oncol Expense 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grimm EA, Mazumder A, Zhang HZ et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155(6):1823–1841.PubMedCrossRefGoogle Scholar
  2. 2.
    Carpentier AF, Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol 2006; 18(6):631–636.PubMedCrossRefGoogle Scholar
  3. 3.
    Jaeckle KA. Immunotherapy of malignant gliomas. Semin Oncol 1994; 21:249–259.PubMedGoogle Scholar
  4. 4.
    Kushen MC, Sonabend AM, Lesniak MS. Current immunotherapeutic strategies for central nervous system tumors. Surg Oncol Clin N Am 2007; 16:987–1004, xii.PubMedCrossRefGoogle Scholar
  5. 5.
    Mitchell DA, Fecci PE, Sampson JH. Immunol Rev 2008; 222:70–100.PubMedCrossRefGoogle Scholar
  6. 6.
    Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000; 46:778–791.PubMedGoogle Scholar
  7. 7.
    Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485–1492.PubMedCrossRefGoogle Scholar
  8. 8.
    Dillman RO, Duma CM, Schiltz PM et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 2004; 27:398–404.PubMedCrossRefGoogle Scholar
  9. 9.
    Hayes RL, Koslow M, Hiesinger EM. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840–852.PubMedCrossRefGoogle Scholar
  10. 10.
    Hayes RL, Arbit E, Odaimi M et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 2001; 39:31–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Jacobs SK, Wilson DJ, Kornblith PL et al. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 1986; 64:743–749.PubMedCrossRefGoogle Scholar
  12. 12.
    Lillehei KO, Mitchell DH, Johnson SD et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991; 28:16–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Merchant RE, Grant AJ, Merchant LH et al. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988; 62:665–671.PubMedCrossRefGoogle Scholar
  14. 14.
    Okamoto Y, Shimizu K, Tamura K et al. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 1988; 94:47–52.CrossRefGoogle Scholar
  15. 15.
    Sankhla SK, Nadkarni JS, Bhagwati SN. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 1996; 27:133–140.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoshida S, Tanaka R, Takai N et al. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988; 48:5011–5016PubMedGoogle Scholar
  17. 17.
    Barba D, Saris SC, Holder C et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70:175–182.PubMedCrossRefGoogle Scholar
  18. 18.
    Blancher A, Roubinet F, Grancher AS et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw 1993; 4:331–341.PubMedGoogle Scholar
  19. 19.
    Boiardi A, Silvani A, Ruffini PA et al. Locoregional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 1994; 39:193–197.PubMedCrossRefGoogle Scholar
  20. 20.
    Bordignon C, Carlo-Stella C, Colombo MP et al. Cell therapy: Achievements and perspectives. Haematologica 1999; 84:1110–1149.PubMedGoogle Scholar
  21. 21.
    Arai S, Meagher R, Swearingen M et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 2008; 10:625–632.PubMedCrossRefGoogle Scholar
  22. 22.
    Ishikawa E, Tsuboi K, Saijo K et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24:1861–1871.PubMedGoogle Scholar
  23. 23.
    Harada H, Saijo K, Watanabe S et al. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res 2002; 93:313–319.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T-cells in antitumor immunity. Trends Immunol 2001; 22:269–276.PubMedCrossRefGoogle Scholar
  25. 25.
    Kruse CA, Cepeda L, Owens B et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T-lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45:77–87.PubMedCrossRefGoogle Scholar
  26. 26.
    Quattrocchi KB, Miller CH, Cush S et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neuro-Oncol 1999; 45:141–157.CrossRefGoogle Scholar
  27. 27.
    Tsuboi K, Saijo K, Ishikawa E et al. Effects of local injection of ex vivo expanded autologous tumor-specific T-lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 2003; 9:3294–3302.PubMedGoogle Scholar
  28. 28.
    Tsurushima H, Liu SQ, Tuboi K et al. Reduction of end-stage malignant glioma by injection with autologous cytotoxic T-lymphocytes. Jpn J Cancer Res 1999; 90:536–545.PubMedCrossRefGoogle Scholar
  29. 29.
    Tsurushima H, Liu SQ, Tsuboi K et al. Induction of human autologous cytotoxic T-lymphocytes against minced tissues of glioblastoma multiforme. J Neurosurg 1996; 84:258–263.PubMedCrossRefGoogle Scholar
  30. 30.
    Holladay FP, Heitz-Turner T, Bayer WL et al. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J Neurooncol 1996; 27:179–189.PubMedCrossRefGoogle Scholar
  31. 31.
    Plautz GE, Miller DW, Barnett GH et al. T-cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000; 6:2209–2218.PubMedGoogle Scholar
  32. 32.
    Sloan AE, Dansey R, Zamorano L et al. Adoptive immunotherapy in patients with recurrent malignant glioma: Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 2000; 9:e9.PubMedCrossRefGoogle Scholar
  33. 33.
    Wood GW, Holladay FP, Turner T et al. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 2000; 48:113–120.PubMedCrossRefGoogle Scholar
  34. 34.
    Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346–2357.PubMedCrossRefGoogle Scholar
  35. 35.
    Peres E, Wood GW, Poulik J et al. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 2008; 39:151–156.PubMedCrossRefGoogle Scholar
  36. 36.
    Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther 2009; 11:37–42.PubMedGoogle Scholar
  37. 37.
    Ishikawa E, Tsuboi K, Saijo K et al. X-irradiation to human malignant glioma cells enhances the cytotoxicity of autologous killer lymphocytes under specific conditions. Int J Radiat Oncol Biol Phys 2004; 59:1505–1512.PubMedCrossRefGoogle Scholar
  38. 38.
    Ishikawa E, Tsuboi K, Takano S et al. Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model. Cancer Sci 2004; 95:98–103.PubMedCrossRefGoogle Scholar
  39. 39.
    Motohashi S, Ishikawa A, Ishikawa E et al. A phase I study of in vitro expanded natural killer T-cells in patients with advanced and recurrent nonsmall cell lung cancer. Clin Cancer Res 2006; 12(20 Pt 1):6079–86.PubMedCrossRefGoogle Scholar
  40. 40.
    Das S, Raizer JJ, Muro K. Immunotherapeutic treatment strategies for primary brain tumors. Curr Treat Options Oncol 2008; 9:32–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Yamanaka R. Dendritic-cell-and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009; 32:265–273.PubMedCrossRefGoogle Scholar
  42. 42.
    Ishikawa E, Tsuboi K, Yamamoto T et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 2007; 98:1226–1233.PubMedCrossRefGoogle Scholar
  43. 43.
    de Vleeschouwer S, Rapp M, Sorg RV et al. Dendritic cell vaccination in patients with malignant gliomas: Current status and future directions. Neurosurgery 2006; 59:988–999.PubMedGoogle Scholar
  44. 44.
    Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res 2005; 11:4160–4167.PubMedCrossRefGoogle Scholar
  45. 45.
    Bracci L, Moschella F, Sestili P et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation and specific tumor infiltration. Clin Cancer Res 2007; 15:644–653.CrossRefGoogle Scholar
  46. 46.
    Liu G, Black KL, Yu JS. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 2006; 5:2332–47.CrossRefGoogle Scholar
  47. 47.
    Guinn BA, Kasahara N, Farzaneh F et al. Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther 2007; 15:1065–1071.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Eiichi Ishikawa
    • 1
  • Shingo Takano
    • 1
  • Tadao Ohno
    • 1
  • Koji Tsuboi
    • 1
  1. 1.Proton Medical Research Center, Graduate School of Comprehensive Human SciencesUniversity of TsukubaTsukubaJapan

Personalised recommendations